Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 600 participants.
Also called NCT03753269
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 600 participants
- Sponsor
- Registry
-
NCT03753269
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT03753269. Randomized; double masking; primary purpose treatment. Start 2019-07-01 (anticipated); primary completion 2022-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction
- Condition
- ST Segment Elevation Myocardial Infarction
- Intervention (Drug)
- Fasudil Hydrochloride
- Intervention (Drug)
- Placebo saline
- Lead sponsor
- RenJi Hospital
Record details
- Record id
cardio:ct-nct03753269- Content hash
3dc597936374fbd9e2a07647134f9847170a4cec5892266d56bad7a35869db27